Private Asset Management Has Lifted Schwab Charles Cp New Com (SCHW) Stake By $2.56 Million; 9 Analysts Bullish Seattle Genetics, Inc. (SGEN)

February 27, 2018 - By Shannon Black

Private Asset Management Inc increased Schwab Charles Cp New Com (SCHW) stake by 940.76% reported in 2017Q3 SEC filing. Private Asset Management Inc acquired 59,475 shares as Schwab Charles Cp New Com (SCHW)’s stock declined 7.92%. The Private Asset Management Inc holds 65,797 shares with $2.88M value, up from 6,322 last quarter. Schwab Charles Cp New Com now has $72.35 billion valuation. The stock increased 1.88% or $0.99 during the last trading session, reaching $53.73. About 5.77M shares traded. The Charles Schwab Corporation (NYSE:SCHW) has risen 32.11% since February 27, 2017 and is uptrending. It has outperformed by 15.41% the S&P500.

Among 18 analysts covering Seattle Genetics (NASDAQ:SGEN), 9 have Buy rating, 0 Sell and 9 Hold. Therefore 50% are positive. Seattle Genetics had 64 analyst reports since July 31, 2015 according to SRatingsIntel. The company was maintained on Monday, July 24 by Piper Jaffray. The company was downgraded on Friday, February 10 by Bank of America. Oppenheimer maintained Seattle Genetics, Inc. (NASDAQ:SGEN) on Monday, July 24 with “Hold” rating. On Friday, June 2 the stock rating was maintained by Oppenheimer with “Hold”. Goldman Sachs initiated the stock with “Sell” rating in Wednesday, November 18 report. SunTrust maintained the stock with “Hold” rating in Friday, October 27 report. The rating was initiated by Oppenheimer with “Hold” on Wednesday, November 8. The rating was maintained by Barclays Capital on Wednesday, July 27 with “Overweight”. On Wednesday, February 14 the stock rating was upgraded by J.P. Morgan to “Buy”. The rating was maintained by RBC Capital Markets with “Outperform” on Friday, July 31. See Seattle Genetics, Inc. (NASDAQ:SGEN) latest ratings:

14/02/2018 Broker: J.P. Morgan Rating: Buy New Target: $66.0 Upgrade
14/02/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Overweight Old Target: $60 Upgrade
07/02/2018 Broker: Needham Rating: Buy New Target: $74.0 Maintain
07/02/2018 Broker: Bank of America Old Rating: Neutral New Rating: Neutral Old Target: $70 New Target: $68 Maintain
07/02/2018 Broker: H.C. Wainwright Rating: Buy New Target: $77.0 Maintain
07/02/2018 Broker: SunTrust Rating: Hold New Target: $60.0 Maintain
01/02/2018 Broker: H.C. Wainwright Rating: Buy New Target: $75.0 Maintain
31/01/2018 Broker: RBC Capital Markets Rating: Buy New Target: $71.0 Maintain
13/11/2017 Broker: RBC Capital Markets Rating: Buy New Target: $69.0 Maintain
08/11/2017 Broker: Oppenheimer Rating: Hold Initiate

The stock increased 1.03% or $0.57 during the last trading session, reaching $55.92. About 592,486 shares traded. Seattle Genetics, Inc. (NASDAQ:SGEN) has risen 75.68% since February 27, 2017 and is uptrending. It has outperformed by 58.98% the S&P500.

Since August 28, 2017, it had 1 insider buy, and 8 selling transactions for $193.59 million activity. SIEGALL CLAY B sold $1.01 million worth of Seattle Genetics, Inc. (NASDAQ:SGEN) on Monday, September 11. SIMPSON TODD E also sold $236,455 worth of Seattle Genetics, Inc. (NASDAQ:SGEN) on Monday, August 28. 8,502 shares were sold by DRACHMAN JONATHAN G, worth $407,199 on Monday, August 28. HIMES VAUGHN B sold 10,000 shares worth $532,190. 7,569 Seattle Genetics, Inc. (NASDAQ:SGEN) shares with value of $397,466 were sold by Cline Darren S. The insider BAKER BROS. ADVISORS LP bought 3.85 million shares worth $200.00 million. 5,343 Seattle Genetics, Inc. (NASDAQ:SGEN) shares with value of $255,900 were sold by DOBMEIER ERIC.

Investors sentiment decreased to 0.78 in Q3 2017. Its down 0.52, from 1.3 in 2017Q2. It worsened, as 51 investors sold Seattle Genetics, Inc. shares while 74 reduced holdings. 29 funds opened positions while 69 raised stakes. 140.23 million shares or 2.00% more from 137.48 million shares in 2017Q2 were reported. Proshare Advsr Llc holds 0.04% in Seattle Genetics, Inc. (NASDAQ:SGEN) or 82,843 shares. The California-based Aperio Gru Limited has invested 0.01% in Seattle Genetics, Inc. (NASDAQ:SGEN). Tributary Mgmt Ltd Limited Liability Company accumulated 19,600 shares. Ameriprise Fincl reported 0% in Seattle Genetics, Inc. (NASDAQ:SGEN). First Advsr Lp stated it has 677,279 shares or 0.09% of all its holdings. Meeder Asset Management Incorporated invested in 201 shares. Tower Research Cap Ltd Co (Trc) invested in 0% or 37 shares. Goldman Sachs Grp Inc Incorporated Inc has 1.29M shares. Fjarde Ap, Alabama-based fund reported 26,874 shares. Creative Planning stated it has 34,620 shares. Tourbillon Capital Lp has 1.06% invested in Seattle Genetics, Inc. (NASDAQ:SGEN). Invesco invested in 0.01% or 349,328 shares. Commerzbank Aktiengesellschaft Fi reported 0.04% stake. Atria Invs Ltd Llc owns 0.02% invested in Seattle Genetics, Inc. (NASDAQ:SGEN) for 5,714 shares. Grandfield And Dodd holds 0.07% or 11,086 shares.

Seattle Genetics, Inc., a biotechnology company, develops and commercializes targeted therapies to treat cancer worldwide. The company has market cap of $8.83 billion. It markets ADCETRIS, an antibody-drug conjugate for relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. It currently has negative earnings. The firm also develops SGN-CD33A that is in Phase III clinical trial to evaluate SGN-CD33A in combination with hypomethylating agents in previously untreated older patients, as well as in Phase 1/2 clinical trial for patients with relapsed or refractory acute myeloid leukemia ; ASG-22ME, which is in Phase I clinical trial for Nectin-4-positive solid tumors, including bladder cancer; SGN-LIV1A that is in Phase 1 clinical trial for patients with LIV-1-positive metastatic breast cancer; and SGN-CD19A, which is in Phase II clinical trial for patients with relapsed DLBCL, as well as in Phase II trial for patients with newly diagnosed DLBCL.

Investors sentiment decreased to 1.03 in 2017 Q3. Its down 0.27, from 1.3 in 2017Q2. It is negative, as 41 investors sold SCHW shares while 299 reduced holdings. 75 funds opened positions while 275 raised stakes. 1.04 billion shares or 0.62% less from 1.05 billion shares in 2017Q2 were reported. Polar Cap Ltd Liability Partnership owns 880,555 shares for 0.43% of their portfolio. Citizens And Northern owns 1.41% invested in The Charles Schwab Corporation (NYSE:SCHW) for 42,223 shares. Hennessy Advsrs Inc, a California-based fund reported 12,500 shares. Aperio Group Inc Inc Lc reported 0.13% of its portfolio in The Charles Schwab Corporation (NYSE:SCHW). Calamos Llc holds 0.06% of its portfolio in The Charles Schwab Corporation (NYSE:SCHW) for 188,723 shares. Sol Cap Mngmt Comm holds 44,745 shares. Lpl Ltd Com holds 183,226 shares or 0.03% of its portfolio. New Mexico Educational Retirement Board reported 0.23% of its portfolio in The Charles Schwab Corporation (NYSE:SCHW). Ameriprise invested in 12.76M shares or 0.27% of the stock. Jnba Advsrs holds 50,655 shares or 0.49% of its portfolio. Ls Ltd Liability holds 0.06% or 23,988 shares. 62,813 are held by Dorsey Whitney Tru Limited Liability. Telemus Ltd Company accumulated 6,310 shares or 0.04% of the stock. Alliancebernstein LP owns 10.86M shares for 0.36% of their portfolio. 10,076 are owned by Capstone Invest Advsr Lc.

Private Asset Management Inc decreased Carnival Corp Cl A (NYSE:CCL) stake by 6,100 shares to 7,650 valued at $494,000 in 2017Q3. It also reduced Schwab Value Adv Money Fd Prem stake by 1.50 million shares and now owns 6.00 million shares. Johnson & Johnson (NYSE:JNJ) was reduced too.

Among 23 analysts covering Charles Schwab (NYSE:SCHW), 15 have Buy rating, 1 Sell and 7 Hold. Therefore 65% are positive. Charles Schwab had 91 analyst reports since August 11, 2015 according to SRatingsIntel. The rating was maintained by Jefferies on Thursday, April 7 with “Buy”. The stock has “Overweight” rating by JP Morgan on Tuesday, September 8. The stock has “Neutral” rating by Citigroup on Friday, April 15. The company was maintained on Friday, October 16 by Compass Point. The rating was maintained by Deutsche Bank on Thursday, June 16 with “Buy”. The stock has “Overweight” rating by Barclays Capital on Thursday, October 13. Suntrust Robinson maintained the shares of SCHW in report on Wednesday, December 27 with “Buy” rating. The company was initiated on Wednesday, March 23 by SunTrust. The rating was upgraded by SunTrust to “Buy” on Tuesday, October 18. The stock of The Charles Schwab Corporation (NYSE:SCHW) has “Buy” rating given on Tuesday, February 6 by Keefe Bruyette & Woods.